Bupropion for Hospital-Based Smoking Cessation

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized blinded trial of whether hospitalized smokers who are randomly assigned to receive bupropion, an antidepressant, and cognitive-behavioral counseling, are more likely to have quit smoking at the end of treatment and at 6 months compared with smokers randomly assigned to receive placebo and cognitive-behavioral counseling. Because depression is more prevalent among smokers and because smokers who are prone to depression may become depressed when they quit, the hypothesis is that the proportion of quitters who receive the active drug/antidepressant will be greater than the proportion of quitters who receive the placebo drug at 6 months.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Treatments: Bupropion

Criteria

Inclusion Criteria:

• currently smoking - use of tobacco products during the week prior to hospital admission and having smoked at least 5 cigarettes /day during the past year

• eligibility to receive medical care in a VA hospital

• hospitalization for at least 48 hours to provide sufficient time to identify, screen, enroll and counsel participants

• willingness to participate and give informed consent

Exclusion Criteria:

• hospitalization for acute CHD syndromes

• contraindications to the use of bupropion

• family history of seizure disorder, history of severe head trauma, predisposition to seizures

• unstable psychiatric disorder

• pregnancy, lactation

• current alcohol (defined as greater than 3 drinks/day) or drug abuse (defined as current/within last 3 months use of narcotics, heroin, cocaine, amphetamines)

• current untreated depression (BDI score > or = 30)

• terminal illness

• inability to be contacted by phone